Gemfibrozil in dyslipidaemia.
A new lipid regulating agent, Gemfibrozil was evaluated in different types of dyslipidaemias. Out of a total of 34 patients, all completed 12 weeks' treatment and 26 completed 24 weeks' of treatment. A significant reduction in total cholesterol, LDL-c triglyceride and apo-B and an increase in HDL cholesterol and its apoprotein--apo-A were observed. The patients belonged to hyperlipidaemias--types IIa, IIb, and IV. Patients' compliance was good and side effects were minimal.
Kundu
S C
SC
Dept. of Biochemistry, B.R. Singh Hosp., Calcutta.
Roxy
S
S
Batabyal
S K
SK
D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D015248:Gemfibrozil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D002784:Cholesterol; D015248:Gemfibrozil